Health Care Innovation
Commentary
USMCA Will Help American Patients
President Trump has often said that he wants to lower drug prices, in part by ending foreign “freeloading.” That’s a laudable goal. Through price controls and other ham-handed policies, too many nations undervalue medical innovation. This leaves Americans with the majority of the world’s research burden. Unfortunately, in an attempt ...
Commentary
Trump drug pricing proposal would doom future cures
President Trump wants to make a deal on drug prices. But his latest proposal could grind medical innovation to a halt. Health and Human Services Secretary Alex Azar said last week that the president was looking for “most favored nation status,” whereby the United States got “the best deal among ...
Drug Pricing
Wayne Winegarden Discusses Drug Price controls on Jim Bohannon Show
Wayne Winegarden, Director for PRI’s Center for Medical Economics and Innovation, discusses the many problems with drug price controls on the nationally syndicated Jim Bohannon Show.
Commentary
There Are High Costs From Implementing Drug Price Controls
Once wide coercive powers are given to government agencies…such powers cannot be effectively controlled. F.A. Hayek As part of the chorus calling for drug price controls, the New York Times editorial page has claimed that “Americans will need to accept a trade-off that other advanced nations long since come around to: Slightly ...
Agriculture
Tales of Woe: How Dysfunctional Regulation Has Decimated Entire Sectors of Biotechnology
“To observe government is to observe the absence of accountability,” James Freeman wrote in the Wall Street Journal.1 That’s certainly true of unwise regulation of many innovative technologies; and modern biotechnology, also known as “genetic engineering (GE)” or “genetic modification (GM),” perhaps along with civilian applications of nuclear power, could be ...
Drug Pricing
Wayne Winegarden Discusses Drug Price Controls on Lars Larson Show
Listen to Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss his recent Forbes op-ed on prescription drug price controls and how they would threaten access to innovative cures for America’s patients on “The Lars Larson Show.”
Commentary
We Need A Cure For The Arrogance Of Drug Price Control Advocates
“Three hundred forty-five billion dollars in savings versus the cost of eight to 15 fewer drugs over 10 years, I frankly think it’s worth it.” Rep. Darren Soto (D-FL), hearing before the House Energy and Commerce Committee In the above quote, Representative Soto is defending H.R. 3, the drug price control ...
Commentary
Medicare’s Denial Of Coverage To Kidney Patients Could Be Just The Beginning
In September 2018, the Centers for Medicare & Medicaid Services (CMS) sent an email announcing that it would no longer cover Auryxia®. Auryxia® is an FDA approved medicine that treats iron deficiency anemia (anemia) for patients with chronic kidney disease (CKD) but who are not on dialysis. People with CKD ...
Business & Economics
NEW ISSUE BRIEF: Biosimilars Study Shows Massive State and Taxpayer Savings Possible by Expanding Biosimilars Market
Biosimilars have the opportunity to bring significant savings to state Medicaid programs and consumers with commercial insurance according to a new study released today by Pacific Research Institute. “Every state would experience significant savings in the state Medicaid programs from expanding the use of biosimilars compared to the more expensive ...
Drug Innovation
Sally C. Pipes Discusses Changing Drug Regulations on the Lars Larson Show
Sally C. Pipes joins the Lars Larson Show on KXL to discuss how new regulations will change drug prices in Canada and discourage drug innovation.
USMCA Will Help American Patients
President Trump has often said that he wants to lower drug prices, in part by ending foreign “freeloading.” That’s a laudable goal. Through price controls and other ham-handed policies, too many nations undervalue medical innovation. This leaves Americans with the majority of the world’s research burden. Unfortunately, in an attempt ...
Trump drug pricing proposal would doom future cures
President Trump wants to make a deal on drug prices. But his latest proposal could grind medical innovation to a halt. Health and Human Services Secretary Alex Azar said last week that the president was looking for “most favored nation status,” whereby the United States got “the best deal among ...
Wayne Winegarden Discusses Drug Price controls on Jim Bohannon Show
Wayne Winegarden, Director for PRI’s Center for Medical Economics and Innovation, discusses the many problems with drug price controls on the nationally syndicated Jim Bohannon Show.
There Are High Costs From Implementing Drug Price Controls
Once wide coercive powers are given to government agencies…such powers cannot be effectively controlled. F.A. Hayek As part of the chorus calling for drug price controls, the New York Times editorial page has claimed that “Americans will need to accept a trade-off that other advanced nations long since come around to: Slightly ...
Tales of Woe: How Dysfunctional Regulation Has Decimated Entire Sectors of Biotechnology
“To observe government is to observe the absence of accountability,” James Freeman wrote in the Wall Street Journal.1 That’s certainly true of unwise regulation of many innovative technologies; and modern biotechnology, also known as “genetic engineering (GE)” or “genetic modification (GM),” perhaps along with civilian applications of nuclear power, could be ...
Wayne Winegarden Discusses Drug Price Controls on Lars Larson Show
Listen to Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss his recent Forbes op-ed on prescription drug price controls and how they would threaten access to innovative cures for America’s patients on “The Lars Larson Show.”
We Need A Cure For The Arrogance Of Drug Price Control Advocates
“Three hundred forty-five billion dollars in savings versus the cost of eight to 15 fewer drugs over 10 years, I frankly think it’s worth it.” Rep. Darren Soto (D-FL), hearing before the House Energy and Commerce Committee In the above quote, Representative Soto is defending H.R. 3, the drug price control ...
Medicare’s Denial Of Coverage To Kidney Patients Could Be Just The Beginning
In September 2018, the Centers for Medicare & Medicaid Services (CMS) sent an email announcing that it would no longer cover Auryxia®. Auryxia® is an FDA approved medicine that treats iron deficiency anemia (anemia) for patients with chronic kidney disease (CKD) but who are not on dialysis. People with CKD ...
NEW ISSUE BRIEF: Biosimilars Study Shows Massive State and Taxpayer Savings Possible by Expanding Biosimilars Market
Biosimilars have the opportunity to bring significant savings to state Medicaid programs and consumers with commercial insurance according to a new study released today by Pacific Research Institute. “Every state would experience significant savings in the state Medicaid programs from expanding the use of biosimilars compared to the more expensive ...
Sally C. Pipes Discusses Changing Drug Regulations on the Lars Larson Show
Sally C. Pipes joins the Lars Larson Show on KXL to discuss how new regulations will change drug prices in Canada and discourage drug innovation.
